Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of EDG-7500 in healthy adults
NCT06011317Phase 1Completed
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edg-7500 in hypertrophic cardiomyopathy (HCM) (3 arms). Primary endpoint: Incidence of treatment-emergent adverse events up to 25 days. Started Aug 2023; status: completed.
02
Drugs
edg-7500
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06011317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011317.